“Science b*tch!” - Jessie Pinkman Amgen, probably…
Rare W for big pharma, so let’s give Lance Armstrong’s favorite drugmaker (read: Amgen) this one. Full results from a late-stage trial show that adding Amgen’s Imdelltra to AstraZeneca’s immunotherapy Imfinzi slashed the risk of death by 58% in patients with extensive-stage small cell lung cancer (read: a fast-growing lung cancer that’s already spread).
The combo pushed median overall survival to 21.1 months, compared with 12.7 months on Imfinzi alone. Nearly 80% of patients on both drugs were still alive after a year, vs. 53% on Imfinzi by itself.
Imdelltra is a hell of a drug…
Friendly reminder, roughly 31,000 Americans get small cell lung cancer every year, and most are already at the extensive stage when they’re diagnosed. Chemo usually works at first… and then the cancer is back on its bullsh*t within months. The trial (DeLLphi-305) tested Imdelltra as maintenance therapy (think: the ongoing stuff after the heavy chemo is done), and the benefit held up even when the cancer had spread to the brain or liver. The data dropped Saturday at the big ESMO cancer conference in Madrid, so $AMGN stonkholders get to react Monday.
Kate Brenan, a 44-year-old mom of two from Denver, started Imdelltra in September 2024 after chemo and radiation. She’s had no evidence of disease since. Genuinely, f*ck cancer.
As for the actual science on this bad boy, Imdelltra grabs a protein on cancer cells and a protein on T cells at the same time and drags the two together (and that’s as much of the nerd talk as I can understand…). Imfinzi takes the brakes off the immune system. In other words, AstraZeneca handles the foreplay and Amgen finishes the job.
Moderna’s old chief medical officer, Paul Burton (now doing the same gig at Amgen… sup, Moderna), called it one of those “moments in medicine” where the data is “so profound that it’s going to transform the standard of care.” Which, fair. He also said Imdelltra could become an “indispensable backbone therapy” for small cell lung cancer, no matter which immunotherapy it’s paired with.
Spoken like a classic drug dealer…
Of course, it’s also very good for business. Imdelltra raked in $627M last year, then went sicko mode in Q2 ($288M, up 115% YoY). That puts it on pace to clear $1B a year, which is what the industry calls a blockbuster. Not bad for a company whose stock shed some pounds after its weight-loss shot, MariTide, underwhelmed in Phase 2 back in 2024.
Right now, Imdelltra is only approved after chemo stops working, and Amgen says it’ll share the new data with regulators. AstraZeneca, for its part, gets to sell a yuge amount more Imfinzi in a combo of equals where Amgen did most of the heavy lifting.
TLDR: Amgen and AstraZeneca are the Mark McGwire and Jose Canseco of small cell lung cancer. Place your bets accordingly, friends…
Until next time!

At the time of publishing, Stocks.News holds positions in Moderna as mentioned in the article.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
